Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Seres Therapeutics, Inc.
The complaint alleges that on September 8, 2014 , Seres announced final data from its Phase 1b clinical trial of SER-109, which yielded positive results including clinical cures and a favorable safety profile. Seres proceeded to Phase 2 of the clinical trial to further evaluate the efficacy of SER-109. Meanwhile, the company shed SER-109 in a positive light, stating that it believed SER-109 …